Current Edition

Current features

Conducting Clinical Trials in the Parallel Virtual Universe

Quantitative systems pharmacology (QSP) and physiologically based pharmacokinetic (PBPK) modelling can be employed to create a parallel virtual workflow throughout d...
Continue Reading →
Current features

Generative AI is Revolutionising Life Sciences, And We’re Just Scratching the Surface

On average, it takes about seven years to develop a new drug and bring it to market. For ambitious life science businesses, generative AI’s ability to generate insig...
Continue Reading →
Volume 15 Issue 4

Transparent, Pret-a-porter Operations Quality Measurement & Other 2024 Priorities for Drug Manufacturers & the Supply Chain

In Life Sciences manufacturing quality and compliance, the global digitalisation drive continues a-pace as the pressure builds to innovate, collaborate and contain c...
Continue Reading →
Volume 15 Issue 4

Diabesity: Implications for Treatment and Drug Development

The term “diabesity” has been used to refer to the twin pandemics of type 2 diabetes (T2D) and obesity.1 It was originally used after experiments showed that overfee...
Continue Reading →
Volume 15 Issue 4

Developing Effective Supply Chain Strategies Utilising Forecasting Technology

Drug development has evolved considerably over recent decades, along with the clinical supply chains that underpin the continued advancement of human health. In t...
Continue Reading →
Regional News

Abzena nabs $65M to bolster manufacturing and research services on both sides of the pond

Roughly one year after dropping designs on a $200 million biologics plant in North Carolina, antibody-drug conjugate specialist Abzena has snared a fresh round of fun...
Continue Reading →
Regional News

Biogen’s Aduhelm call to action backfires as CMS receives many more comments in favor of restrictive coverage: analyst

During a January Q&A call with investors, Biogen chief Michel Vounatsos pressed Aduhelm supporters to fight the Centers for Medicare & Medicaid Services’ (CMS...
Continue Reading →
Regional News

Novartis, Amgen settle their dueling lawsuits over migraine drug Aimovig

Novartis and Amgen have spent years arm wrestling one another over their development and commercialization deal on migraine prevention drug Aimovig. Now, the parties ...
Continue Reading →
Regional News

Eyeing its post-Humira future, AbbVie angles for broader Rinvoq use in U.S., Europe

Despite classwide safety worries in the U.S., AbbVie is making strides in its quest to build immunology up-and-comer Rinvoq. AbbVie sent off applications to U.S. and...
Continue Reading →
Regional News

After its $7.6B buyout fell through, Sobi scores NICE backing for rare disease drug Aspaveli

After rare disease drugmaker Sobi reportedly had a buyout scuppered by pharma giant AstraZeneca, the company has picked up a win that stands to bolster its Aspaveli l...
Continue Reading →